10x Genomics announced that it has shipped more than 100 Xenium Analyzer instruments in the eight months since the platform’s launch. The milestone reflects strong customer demand for the Xenium platform, which is increasingly recognized as the best performing system for in situ analysis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TXG:
- 10x Genomics price target raised to $70 from $65 at Canaccord
- 10x Genomics price target raised to $70 from $66 at TD Cowen
- 10x Genomics price target raised to $75 from $65 at Citi
- 10x Genomics raises 2023 revenue view to $600M-$630M from $590M-$610M
- 10x Genomics reports Q2 EPS (53c), consensus (40c)